Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Zevra Therapeutics's price to sales ratio was 5.2× on Nov 11, 2026, against 5.6× a year earlier. Over the last 5 years it ranged from 4.5× to 21.9×, with a median of 10.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.2× | −0.8 |
| 2025 | Dec 31, 2025 | 6.0× | −12.2 |
| 2024 | Dec 31, 2024 | 18.1× | +3.8 |
| 2023 | Dec 29, 2023 | 14.3× | −0.5 |
| 2022 | Dec 30, 2022 | 14.8× | +4.0 |
| 2021 | Dec 31, 2021 | 10.8× | +6.7 |
| 2020 | Dec 31, 2020 | 4.1× | – |
See a number that looks wrong?